Reiki Therapy to Improve Symptoms During Brachytherapy for Gynecological Cancers
Led by University of Utah · Updated on 2026-05-11
70
Participants Needed
1
Research Sites
43 weeks
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating the effects of Reiki therapy on symptoms experienced by patients receiving their first brachytherapy treatment for gynecological cancers such as endometrial, cervical, vaginal, or vulvar cancer. This open-label, randomized, controlled clinical trial conducted by the University of Utah aims to compare Reiki therapy to usual care in managing anxiety, pain, depression, and physiological responses during treatment.
Participants are randomly assigned to receive either a session of Reiki therapy or standard care during the usual waiting period between the placement of the brachytherapy device and the start of treatment. Reiki therapy involves a trained practitioner channeling energy through their hands while the patient lies quietly with optional calming music and aromatherapy. The control group remains in a clinic room during this time and may engage in any activity except Reiki therapy, and they may be accompanied by a family member or friend.
Participants complete questionnaires on anxiety, pain, and depression at multiple times on the day of their first brachytherapy treatment and again at a three-month follow-up. The study also monitors physiological measures including respiratory rate, heart rate, blood pressure, and oxygen saturation. The primary outcome compares changes in anxiety levels using the Spielberger State Anxiety Scale from before the intervention to follow-up. Participation lasts at least three months to assess both immediate and longer-term effects.
CONDITIONS
Brief Title
Using Reiki Therapy to Improve Symptoms Associated With Brachytherapy in Patients With Gynecological Malignancies
Research Team
D
David Samuel
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
Factors
Reiki Therapy plus Brachytherapy
Standard Care (Brachytherapy Alone)
What is it?
Reiki therapy is a form of Japanese energy healing administered by a trained practitioner who places hands on or near the patient with the intent to promote well-being. In the trial setting, Reiki is given during outpatient brachytherapy appointments.
Standard care in this setting is outpatient brachytherapy with routine supportive measures, without Reiki or specific energy therapy techniques.
Role in the trial
Tested as a potential adjunct to standard supportive care during brachytherapy to evaluate effects on anxiety, pain, and other symptoms.
Serves as the comparison arm reflecting usual brachytherapy delivery, used to measure differences from Reiki therapy addition.
Primary use or purpose
Explored for reducing anxiety and pain associated with brachytherapy for gynecologic cancers.
Provides evidence-based brachytherapy as standard treatment for eligible gynecological malignancies.
How it is given or performed
A certified Reiki practitioner places hands lightly on or just above the patient's body during brachytherapy sessions, in a calming environment that may include music or aromatherapy based on patient preference.
Brachytherapy is delivered as a scheduled outpatient procedure by a radiation oncology team following standard protocols, without additional adjunctive energy therapies.
Evidence status
Evidence from small randomized and non-randomized studies suggests Reiki may help reduce anxiety or pain in cancer patients, but data remain limited, especially in the setting of brachytherapy.
Brachytherapy is considered an evidence-based, essential part of treatment for endometrial, cervical, vaginal, and vulvar cancers, supported by strong guideline recommendations.
Important limitations
Reiki research in cancer is limited by small studies, variable session protocols, and absence of blinding; generalizability to all patients remains unclear.
Even with guideline-based brachytherapy, patients may experience anxiety, pain, or distress, which are not always fully relieved by standard supportive care.
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
Who Can Participate
Age: 18Years +
FEMALE
Eligibility Criteria
You may qualify if you...
Female aged 18 years or older
Pathologically confirmed cancer of the endometrium, cervix, vagina, or vulva
Eligible for outpatient brachytherapy treatment
Able to read and understand English or Spanish
Able to provide informed consent and willing to sign consent form
Willing to participate in either Reiki therapy or standard care group
You will not qualify if you...
Prior brachytherapy treatment for a gynecological cancer
Medical, psychiatric, cognitive, or other conditions that affect ability to understand information, give consent, comply with study protocol, or complete the study
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Treatment
Duration - During the standard wait time before first brachytherapy treatment
Participants receive either a session of Reiki therapy during the standard wait time between the placement of the brachytherapy device and their first brachytherapy treatment, or remain in a clinic room during this wait time without Reiki therapy.
1 visit (in-person)
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Phase 01 Study Evaluating Safety and Dose of 177Lu-RAD204, a Radiolabeled Antibody Targeting PD-L1, in Adults With Advanced PD-L1 Positive Solid Tumors
Phase 12a Study of 177Lu-BetaBart, a Radiolabeled Anti-B7-H3 Antibody, for Safety and Early Effectiveness in Adults with Relapsed or Metastatic Solid Tumors
Evaluating 18F-T2 PETCT Imaging for Detecting Tumors with High CAIX Levels in Adults
Study of Using 3D-Printed Custom Devices for High-Dose Radiation Treatment in Gynaecological Cancer
Phase 12 Study of MDNA11, a Beta-only IL-2 Therapy, Alone or With Pembrolizumab for Advanced Solid Tumors
A Phase 3 Study Testing Sacituzumab Tirumotecan With Pembrolizumab, With or Without Bevacizumab, Compared to Standard Care for Women With Advanced or Recurrent Cervical Cancer
Phase III Study Comparing BNT323DB-1303 to Chemotherapy in Women With Recurrent HER2-Positive Endometrial Cancer
Safety and Feasibility Study of PVX7 Immunotherapy for Advanced Cervical Cancer in Women Who Completed Primary Treatment
Study on Cervical and Endometrial Cancer in Women Aged 20 to 75
Phase I Study of Cardunizumab Combined with Pulsed Low-dose Rate Radiation for Recurrent Lung, Esophageal, and Cervical Cancers
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Brachytherapy: A critical component of primary radiation therapy for cervical cancer: From the Society of Gynecologic Oncology (SGO) and the American Brachytherapy Society (ABS).
Christine H Holschneider, Daniel G Petereit, Christina Chu...